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Small extracellular vesicles (sEVs) are those nanovesicles 30–150 nm in size with a
role in cell signalling and potential as biomarkers of disease. Nanoparticle tracking
analysis (NTA) techniques are commonly used to measure sEV concentration in biofluids.
However, this quantification technique can be susceptible to sample handing and
machine settings. Moreover, some classes of lipoproteins are of similar sizes and
could therefore confound sEV quantification, particularly in blood-derived preparations,
such serum and plasma. Here we have provided methodological information on NTA
measurements and systematically investigated potential factors that could interfere
with the reliability and repeatability of results obtained when looking at neat biofluids
(i.e., human serum and pericardial fluid) obtained from patients undergoing cardiac
surgery and from healthy controls. Data suggest that variables that can affect vesicle
quantification include the level of contamination from lipoproteins, number of sample
freeze/thaw cycles, sample filtration, using saline-based diluents, video length and
keeping the number of particles per frame within defined limits. Those parameters
that are of less concern include focus, the “Maximum Jump” setting and the number
of videos recorded. However, if these settings are clearly inappropriate the results
obtained will be spurious. Similarly, good experimental practice suggests that multiple
videos should be recorded. In conclusion, NTA is a perfectible, but still commonly used
system for sEVs analyses. Provided users handle their samples with a highly robust
and consistent protocol, and accurately report these aspects, they can obtain data that
could potentially translate into new clinical biomarkers for diagnosis and monitoring of
cardiovascular disease.
Keywords: cardiac surgery, exosome (vesicle), exosomal biomarkers, nanopartcicles, NTA (nanoparticle tracking
analysis)
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BACKGROUND
Small extracellular vesicles (sEVs) are generally in the region
of 30–150 nm in size and are released from all cells. They
are a heterogeneous group of nanoparticles of different cargo
content and function, including exosomes (Giulietti et al., 2018).
They have become of great interest due to their emerging role
in cell-to-cell communication (Théry et al., 2002; Emanueli
et al., 2015), through their ability to transfer their active
molecular cargoes to recipient cells. Additionally, they can
use surface proteins to activate cell signalling pathways in the
cells they come into contact with. However, given their small
size, established methods, such as standard flow cytometry,
which can, for example, be applied to identify and quantify
larger EVs, cannot be used directly to investigate concentrations
of small EVs (Emanueli et al., 2015; Coumans et al., 2017).
In recent years a technique originally developed for other
industrial applications, nanoparticle tracking analysis (NTA),
has been adapted for this purpose (Dragovic et al., 2011).
NTA has become a staple technique in the toolbox of sEV
researchers, with the recognition that certain procedures have
to be followed to ensure reliable and repeatable data are
produced (Filipe et al., 2010; Gardiner et al., 2013; Maas
et al., 2015; Tian et al., 2016; Parsons et al., 2017; Vestad
et al., 2017). Parsons et al. (2017) showed that the precision
of routine NTA measurements can be significantly improved
for different biofluids by increasing video replicates. Other
studies proposed the use of silica microspheres for calibration
to overcome differences between instruments with different
specifications (Gardiner et al., 2013) or the use of instrument-
optimised settings to correct significantly different results
observed between different instruments with identical software
settings (Vestad et al., 2017). Although NTA camera level and
detection threshold were determined as significant factors in
the quantification of liposomes, changing these variable settings
were less prominent for sEV quantification (Filipe et al., 2010;
Gardiner et al., 2013; Maas et al., 2015). Sample heterogeneity,
operator and software version were reported as other factors
affecting the accuracy of NTA measurements (Vestad et al., 2017;
Bachurski et al., 2019).
We will build on and expand these observations, specifically in
relation to neat serum and pericardial fluid (PF) prepared from
cardiovascular patients, with the intention of producing a “how
to” guide for analysing these samples using NTA.
When analysing neat biofluids, particularly the ones
deriving from blood, it must be taken into account that
the size of sEVs and lipoproteins overlap partially. This is
true for the following classes of lipoproteins: chylomicrons
(75 nm–1.2 µm), chylomicron remnants (30–80 nm),
very low density lipoproteins (VLDL: 30–80 nm) and
intermediate-density lipoproteins (ILDL: 25–35 nm)
(Feingold and Grunfeld, 2000).
One potential use for sEVs in the clinic is as biomarkers
of disease, particularly through the extraction of sEVs from
bodily fluid as a “liquid biopsy.” It is therefore important to
standardise methodologies in place in order to demonstrate
this. In many cases the biomarker studies involving sEVs
have focussed on their molecular cargo, especially microRNAs
(miRs) (Alegre et al., 2016; Manier et al., 2017; Selmaj et al.,
2017). This aspect has considerable potential, but it might
necessitate sEV extraction followed by molecular analyses, thus
adding complexity and delay between taking the sample and
obtaining the result. This is not ideal when an early diagnosis or
prognostic indicator is necessary, such as in patients presenting
with a suspected myocardial infarction, or to assess the risk
of early complications following cardiac surgery. These and
other situations are where, potentially, acute changes in sEV
concentration or their size could be used (Cappello et al.,
2017). We demonstrated, for example, that dramatic changes in
plasmatic sEV-size particle concentrations could be detected in
patients undergoing coronary artery bypass graft surgery (CABG)
under cardiopulmonary bypass (CPB). We also demonstrated
that, following surgery, the size of these particles changed and
that they contained miRs (such as miR-1 and miR-133a/b) known
to be enriched in the myocardium and whose concentration also
increased significantly in both the plasma and plasma-derived
sEVs (Bachurski et al., 2019). It is therefore conceivable that the
plasma nanoparticle changes were caused by their induced release
by the myocardium as a response to the ischaemia/reperfusion
injury induced by the surgery. In line with this, both the
sEV plasma concentration (measured by NTA) and the cardiac
miRs in the sEVs were highly correlated with high sensitivity
cardiac troponins (hs-cTNs), the gold standard biomarker for
myocardial injury (Emanueli et al., 2016). We used neat plasma
samples when carrying out NTA in this study, which is unusual
among sEV studies, as others have extracted the sEVs from
the plasma first (Vicencio et al., 2015). Our approach presents
additional challenges when using NTA, such as the presence of
a multitude of other particles and proteins in the sample that can
confuse the tracking software. However, the currently available
protocols for sEVs extraction are intrinsically associated with
sEV loss (Lobb et al., 2015; Patel et al., 2019) and, especially
in the case of plasma or serum, they have not be able to
resolve the problem of protein and lipoprotein contaminations.
Moreover, for potential applications in an acute bedside-testing
type setting, the minimal handling offered by analyses on neat
biofluid is remarkable.
There are a number of potential sources of error that
should be taken in consideration when designing protocols
for studies involving clinical samples using an NTA system.
These have not been systematically demonstrated. For example,
the handling of a sample from the immediate point at
which it is taken has been suggested to introduce variability
in the sEV content (Witwer et al., 2013). Similarly, it
has also been suggested that storage and freeze-thaw cycles
could have an impact on sEV integrity and aggregation
(Bosch et al., 2016). This does not appear to be conclusive
but, if true, has the potential to lead toward additional
variability in results, particularly if samples are not handled
consistently. We have thus carried out a thorough investigation
such that we are able to suggest important methodological
considerations for the quantification of nanoparticles in bodily
fluids using some of the most up-to-date software and hardware
available for NTA.
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METHODS
General Setup
All experiments were carried out using a NanoSight NS300
(Malvern PANalytical, Malvern, United Kingdom), with NTA
software version 3.2 (Malvern Instruments). All samples were
diluted using Gibco phosphate buffered saline (PBS, catalogue
number 14190094) (Thermo Fisher, Paisley, United Kingdom)
except where otherwise noted. The PBS was filtered prior to
use using a Millex 33 mm, 0.22 µm syringe filter unit (Merck,
Nottingham, United Kingdom). Samples were vortexed briefly,
filtered using a 4 mm, 0.22 µm Millex syringe filter unit
(Merck), except where otherwise noted, then taken up into
a 1 mL BD Plastipak syringe (BD Biosciences, Wokingham,
United Kingdom) and injected into the flow cell of the NanoSight
NS300. Once loaded, the sample was passed through the system
using a syringe pump at a rate of 50 arbitrary units (A.U.),
decreased gradually through 500, 300, 200 and 100 A.U. Once
stable, this flow rate allows the particles to pass across the field
of view in approximately 8 s. A video would then be captured and
processed (script attached, Supplementary File 1).
Sample Collection
Samples were handled in accordance with the Declaration of
Helsinki and the Human Tissue Act. The samples used in this
study were collected as discarded tissue from different cardiac
surgery patients operated on at our Centre and from healthy
controls who provided informed consent. Samples were covered
by ethical approvals from the UK National Research Ethic Service
NRES (REC 10/H0107/63, 12/LO/1361, 13/LO/1687). Blood was
collected in an SST Advance vacutainer (BD Biosciences) and
transferred to the lab within 1 h, where it was double-centrifuged
at 2240 × g and RT for 10 min to produce serum. The sera were
quickly aliquoted and immediately frozen and kept at −80◦C
until use. Pericardial fluid was collected following the opening of
the pericardial sac at the beginning of heart surgery. The PF was
then moved to the lab and spun at 4◦C at 300× g for 5 min to and
the supernatant collected. The supernatant was then spun again
at 13000× g for 5 min. The supernatant was collected and stored
at−80◦C until use.
Investigation of Sample Composition
Nanoparticle counts were registered in parallel from the whole
serum and sEVs isolated from the serum by size exclusion
chromatography (SEC). sEVs were isolated as previously
described (Beltrami et al., 2017) and tested for ApoA1 and
ApoB by ELISA kits (ab108803, ab190806, Abcam, Cambridge,
United Kingdom). This was performed in serum samples
collected before and at 24 h following cardiac surgery (n = 6) to
investigate if the serum nanoparticle counts followed the trend
observed when measuring serum-derived sEVs. To completely
explore the composition of the serum samples, we also considered
the presence of high density lipoproteins (HDLs) and VLDL.
To do that, we measured apolipoprotein A1 (ApoA1, which is
paramount of the HDLs) and ApoB (characteristic from LDLs,
IDLs, VLDLs and chylomicrons).
Initial Preparation of the NTA
The optical glass of the laser module was initially wiped with a
tissue dampened with:
1. 70% IMS.
2. MilliQ water.
3. 1% ethanoic acid (Sigma-Aldrich, Dorset,
United Kingdom).
4. MilliQ water.
Following this, the low-volume flow cell was attached to the laser
module and the system flushed with:
1. 1 mL 10% ethanol (Sigma-Aldrich).
2. 1 mL filtered Gibco PBS (Thermo Fisher).
3. 1 mL filtered Gibco PBS.
The machine was then considered ready for use.
Standard Washing Procedure
The standard, non-automated, washing procedure adopted in
this protocol was as follows:
1. 1 mL filtered Gibco PBS.
2. 1 mL filtered Gibco PBS.
3. 1 mL 1% ethanoic acid.
4. 1 mL filtered Gibco PBS.
5. 1 mL filtered Gibco PBS.
This was carried out prior to running any standard or sample.
Standard Machine Settings
Unless otherwise stated, recordings were made using settings
previously chosen to give the best contrast in our experience,
using the NS300:
• Slider Shutter: 1300
• Slider Gain: 512
• Camera Histogram Upper Limit: 2470
• Camera Histogram Lower Limit: 130
• Syringe Pump Speed/AU: 50
Focus was set manually according to manufacturer’s
instructions, ensuring that the maximum number of particles
was in focus in the field of view, by maximising the central blob
intensities and minimising the ring intensity (diffraction rings
that can occur when particles are correctly focussed) to reduce
non-zero-order peaks.
Calibration and Reproducibility
We used a commercially available sEV standard consisting of
sEVs derived from the plasma or serum of healthy human
controls (HansaBioMed, Tallinn, Estonia) as a calibrator. The
standard was diluted according to manufacturer’s instructions,
aliquoted, then frozen in individual aliquots for single use. On
each day of NTA use, a new aliquot was prepared into a working
dilution suitable for running on the NanoSight by adding 5 µL
of the standard to 995 µL PBS, giving a 1:200 dilution. Four 90-s
videos were recorded under flow conditions and processed using
Detection Threshold 9. This was repeated over 25 days to observe
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day-to-day variations, quantifying particle concentration and the
number of particles in the 90–120 nm range.
Serum Sample Preparation
Except for when testing diluents, serum was thawed for 30 min at
RT and initially prepared for analysis by NTA at a 1:100 dilution
by diluting 10 µL of sample with 990 µL PBS; 200 µL of this
initial dilution was added to 800 µL PBS, to give a final 1:500
dilution. For the diluent experiment, 1:500 was not feasible for
technical reasons (i.e., not sufficient to allow for particle detection
when using water). Therefore, in this instance, serum samples
were prepared at a 1:100 dilution using the diluent to be tested,
then further diluted using 900 µL of the diluent and 100 µL of
the sample to ultimately give a working dilution of 1:1000.
Pericardial Fluid Sample Preparation
Pericardial fluid was thawed for 30 min at RT, then diluted 1:50.
This was achieved by diluting 20 µL sample with 980 µL PBS.
This dilution was also used for the diluent experiment.
Investigating the Effect of Sample
Freeze-Thaw Cycles on Particle Count
Each serum or pericardial sample was prepared and run
according to our standard protocol. The original sample was then
re-frozen at−70◦C. The same sample was subsequently defrosted
and run again using the same settings and again re-frozen. This
was repeated twice more. Time-points were defined as: T0 – first
defrosting of sample having been freshly frozen, T1 – second
defrosting, T2 – third defrosting, T3 – fourth defrosting. Each
sample thawed on the bench and was re-frozen overnight before
thawing again the following day.
Investigating the Effect of Different
Diluents on Sample Particle Count
Initial manufacturer recommendations suggest that one should
use water for diluting a sample for analysis with NTA, which
might not be suitable for biological samples, as there is the
possibility that biological vesicles could lyse due to osmotic
potential. We investigated the effect on particle count of using
different diluents to dilute both serum and PF samples. The
diluents tested were the PBS we have used in our other
experiments in this paper, simulated body fluid (SBF), Hanks
Balanced Salt Solution (HBSS, Sigma-Aldrich, catalogue number
H1387) and filtered, deionised water. SBF was prepared as
previously described (Gu et al., 2010). HBSS was prepared
according to the instructions supplied by the manufacturer. Four
videos of 90s were acquired for each of the different diluents and
processed using the standard settings above.
Investigating the Effect of Sample
Concentration
The sEV standard was initially prepared as above. Dilutions were
made in filtered Gibco PBS (Table 1). The sample of the standard
was then run and analysed on the NanoSight using the settings
above, except that 3 90-s videos were recorded instead of 4 and
the fold dilution recorded by the software as 1, rather than the
actual fold dilution.
Investigating the Effect of Particle
Masking
By “masking” we refer to a large particle hiding a smaller particle
and thus excluding it from the total NTA count. Firstly, as a proof
of principle for the issue of masking, 100 nm (NTA 4088) and
200 nm (NTA 4089) Latex Standard beads (Malvern) were diluted
in PBS and used alone or in combination. 100 nm standards
were diluted 1:1000, while 1:100 dilution was used for 200 nm
standards. This meant that when 100 and 200 nm standards were
combined, their ratio was 1:10 respectively. Three 30-s videos
were recorded and all videos were processed using a Detection
Threshold of 8. We hypothesise that a mixture of 100 nm and
200 nm particles would result in reduced counts in the sEV
range due to masking.
The effect of particle masking was further explored using
serum or PF samples, prepared as above. Four 90-s videos
were acquired. The analysis was carried out using Detection
Threshold 9. These were compared with the unfiltered equivalent
sample, i.e. prepared in the same way, except that the
filtration step was excluded. Again, we hypothesise that the
unfiltered samples would have lower counts in the small EV
range due to masking.
Investigating the Effect of Video Length
and Number of Videos
A serum or PF sample was prepared and four videos were
recorded, using 30, 60, 90, 120, 150 and 180 s acquisitions. All
videos were processed using a Detection Threshold of 9. A fresh
sample was prepared for each test of video length. The flow
cell was cleaned (as per the standard protocol) between each
sample. The data recorded using videos of 90 s in length was
also arbitrarily used to investigate the effect of the number of
TABLE 1 | Dilutions of plasma calibrator to determine linearity.
Fold dilution 1st dilution 2nd dilution (of 1st dilution)
Vol standard
(µL)
Vol PBS
(µL)
Vol diluted
standard (µL)
Vol PBS
(µL)
20 50 950 – –
40 25 975 – –
50 20 980 – –
66.67 15 985 – –
100 10 990 – –
125 8 992 – –
142.875 7 993 – –
200 5 995 – –
250 4 996 – –
333.33 3 997 – –
400 10 990 250 750
500 10 990 200 800
800 10 990 125 875
1000 10 990 10 990
2000 10 990 50 950
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videos recorded on the results, comparing the standard deviation
in particle concentration readings between acquisitions with 2,
3 and 4 recordings. We hypothesise that longer acquisition time
and higher number of videos would result in smaller variability
(standard deviation) of the sEV counts.
Investigating the Effect of Changing
Focus
A serum sample was prepared and four videos of 90 s each
were recorded with the focus set correctly, as described above,
then 10 and 30 A.U. below optimum. The videos were recorded
consecutively, without pausing the syringe pump. Following the
standard washing procedure, the experiment was repeated with a
fresh sample, this time increasing the focus 10 and 30 A.U. above
optimum. All videos were processed using a Detection Threshold
of 9. The same experiment was carried out with PF, varying the
focus by 10 or 30 A.U. in each direction.
The Effect of Maximum Jump Distance
The “Maximum Jump” setting is used by the NTA software to
determine how far it needs to “look” for a particle as it moves
from one frame to the next in the video. The smaller the particle,
the further it will move between frames and therefore a larger
search area is required by the software to track it successfully.
This is a setting which can be set to “Auto” and the software
scans through the first 100 frames of the video to determine the
optimum setting. However, there can be small changes between
videos, so potentially this can introduce variability to the results.
We investigated how manually keeping this setting constant
affects the readings, compared to the automatic setting. Serum
and PF samples were prepared as above and loaded into the
machine. The same sample was then run four consecutive times
on the same settings as above. The maximum jump setting was
set to “Auto” for the first run, 14 A.U. for the second, 20 A.U. for
the third and 10 A.U. for the fourth. Videos were analysed using
Detection Threshold 9.
Data Analysis
NanoSight Raw Data outputs were used in all analyses. All
graphs show concentration/particle count data as mean ± SD.
The magnitude of the effect of a variable is presented as a
percentage change. Additionally, we present the variability in
measurements, as observed by changes in the SD of the data.
Whilst the focus is generally to observe the magnitude of changes
induced by different settings, in some cases where a hypothesis
was formulated in relation to a specific variable a statistical
test was performed, using non-parametric tests (Mann–Whitney
test, Wilcoxon test, Friedman test or Kruskal–Wallis test with
Dunn’s post hoc test, as appropriate) with p < 0.05 indicating
statistical significance.
RESULTS
Samples
Particle count results to characterise the serum samples
revealed no significant difference when comparing whole serum
measurements and isolated sEVs, suggesting that whole serum
mimics the isolated sEVs. This was observed at all relevant
particle ranges (30–60, 61–90, 91–120 and >121 nm) as shown
in Figure 1. As confirmation of scarce lipoprotein presence
on the isolated sEVs, ApoA1 and ApoB sharply decreased in
isolated sEVs in comparison to the whole serum (Figures 1B,D).
This was observed also when samples were divided according
to timing of surgery (i.e., pre/post-surgery; Figures 1C,E), with
ApoB interestingly showing increased values post-surgery.
Calibration and Reproducibility
Four runs using the sEV standard were carried out and the raw
traces of each of the recordings were superimposed (Figure 2A).
Importantly, there was little day-to-day variability in calibrator
concentration over a 25-day time period (≤6%), in terms of either
total particle concentration (Figure 2B) or percentage particles in
the 90–120 nm range, as a reference size range (Figure 2C).
Repeated Freeze-Thaw Cycles Tend to
Increase in Particle Count
With serum, we saw an increase in the number of particles
in the sEVs range (30–120 nm) with more freeze-thaw
cycles [3.72 × 1011 ± 1.37 × 1010 particles/mL at T0,
4.73 × 1011 ± 2.83 × 1010 particles/mL at T1 (27% increase over
T0), 5.77 × 1011 ± 1.46 × 1010 particles/mL at T2 (55% increase
over T0, p = 0.006), Figure 3A]. The percentage of particles
in this size range relative to the total particle concentration
did not appear to vary (85% at T0, 82% at T1, 83% at T2,
84% at T2, Figure 3B). There was also an increase in the
particle concentration in the 121–210 nm size range (p = 0.016
T2 vs. T0) (Figure 3C), and no differences in the percentage
particles in this size range (Figure 3D). Therefore, there was an
increase in the total number of particles, with a 58% increase
between T0 (4.36 ± × 1011 8.34 × 109 particles/mL) and T2
(6.91× 1011 ± 2.18× 1010 particles/mL, Figure 3E, p = 0.006).
Pericardial fluid also showed a trend toward increasing
particle counts with increasing freeze-thaw cycles. The 30–
120 nm particles increased by 27% from 2.92× 1010 ± 1.15× 109
particles/mL at T0 to 3.72 × 1010 ± 3.43 × 109 particles/mL
at T3 (p = 0.037, Figure 3F). Both the particle counts from
121 to 210 nm (3.48 × 1010 ± 1.11 × 109 particles/mL at T0
to 4.61 × 1010 ± 1.71 × 109 particles/mL at T3, p = 0.006,
Figure 3G) and total particles (8.05 × 1010 ± 2.560 × 109
particles/mL at T0 to 1.03 × 1011 ± 1.71 × 109 particles/mL
at T3, p = 0.006, Figure 3H) increased consistently (32 and
28% respectively).
Different Diluents Give Different Results
for the Same Sample
For both serum and PF, the particle count in water was
substantially higher than in any of the other diluents. For serum
in particular, the particle count was approximately threefold
higher in water (15.9 × 1011 ± 1.9 × 1011 particles/mL vs.
5.8 × 1011 ± 1.3 × 1010 in SBF, 5.4 × 1011 ± 2.3 × 1010 in
HBSS, and 5.9× 1011 ± 3.6× 1010 in PBS). For PF, particle count
was 13% higher in water (4.6 × 1010 ± 1.2 × 109 particles/mL)
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FIGURE 1 | Small EVs vs. whole serum nanoparticles. (A) Comparison of nanoparticle concentration by size range. (B) ApoB quantification on small EVs and whole
plasma in all samples. (C) ApoB quantification on small EVs and whole plasma in Pre- and Post-surgery samples. (D) ApoA1 quantification on small EVs and whole
plasma in all samples. (E) ApoA1 quantification on small EVs and whole plasma in Pre- and Post-surgery samples. *p < 0.05.
than SBF (4.1 × 1010 ± 1.19 × 109 particles/mL), 24% higher
than HBSS (3.7 × 1010 ± 1.45 × 109 particles/mL) and 61%
higher than PBS (2.84 × 1010 ± 5.57 × 108 particles/mL). This
is illustrated in Figure 4.
Overcrowded Samples Result in
Underestimation of Nanoparticles
We observed that, as the number of particles per frame increases,
so does the particle concentration, in a linear fashion (R2 = 0.99).
If we compare the fold dilution of the sample with either the
particles per frame or measured particle concentration, this
results in a non-linear curve (Table 2 and Figures 5A,C). This
suggests that there comes a point where the machine over- or
under-estimates the particle concentration, due to there being
too few or too many particles per frame. There is a section of
this curve which is, indeed, largely linear, between a fold dilution
of 66.67 and 250 (R2 = 0.93, Figure 5D), corresponding to a
particle-per-frame range 39–110 (Figure 5B).
The Effect of Masking: Filtration
Increases Particle Count
The effect of masking was demonstrated in the first instance
by the latex beads experiment. The recorded 30–120 nm
particle concentration of latex beads decreases by 91% from
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FIGURE 2 | Calibration. (A) Traces of four consecutive videos, closely
superimposed one on top of the other. (B) Total particle concentration of
calibrator. (C) Percentage particles in the 90–120 nm range. Lines on (B,C)
represent mean concentration and %, respectively.
1.34 × 1011 ± 1.35 × 1010 particles/mL 100 nm beads alone, to
1.18× 1010 ± 8.54× 108 particles/mL when mixed with 200 nm
beads (p ≤ 0.013, Figure 6A). The 200 nm bead concentration,
however, shows very little change (4.55 × 1010 ± 3.06 × 109
particles/mL 200 nm beads alone vs. 4.80 × 1010 ± 2.50 × 109
particles/mL when mixed with 100 nm beads, an increase of 6%).
This was confirmed by observing the effect of filtration. An
increase of 78%, from 3.64 × 1011 ± 3.184 × 1010 particles/mL
in the nanoparticle concentration in an unfiltered serum sample
to 6.48 × 1011 ± 1.77 × 1010 particles/mL in a filtered sample
(p = 0.029, Figure 6B) was recorded. Repeating the test on PF
gave an increase in particle count in a filtered sample of 21% over
an unfiltered sample (1.23 × 1010 ± 1.69 × 109 particles/mL
unfiltered vs. 1.49 × 1010 ± 1.65 × 109 particles/mL filtered,
p = 0.029, Figure 6C). This suggests that this effect is less
noticeable in PF than in serum.
Increasing Video Length, Up to a Point,
Increases Particle Concentration
It stands to reason that the longer the video recordings are,
the more events that will be captured and, therefore, the more
opportunity the software has to track particles, thereby reducing
the variability in the particle count between recordings and
increasing the robustness of the result. Particle concentration
in serum peaked at 90s video length (Figure 7A). Particle
concentration in the 30–120 nm range varied by 6% from 30s
to 90s. Interestingly, the number of counted particles begins to
decrease beyond 90s, with a 30% decrease being observed for a
180s video, compared to 90s. The particle count at 90s also saw
the lowest SD (1.93 × 1010). Repeating this experiment using
PF gave similar results (Figure 7B). The highest particle count
in the 30–120 nm range in this case was given by recordings
of 150s, which were 12% higher than those calculated by 90s
videos, however with a higher standard deviation (1.63 × 109 vs.
1.17× 109 particles/mL).
The Number of Recordings Has a
Limited Impact on Particle Count
Overall, low variability between particle counts in the sEV range
was observed when testing the effect of multiple recordings. We
saw that with the PF, the SD remained very similar with an
increasing number of videos. There was, however, an increase
in the standard deviation with an increase in the number of
videos when looking at serum (Table 3). However, the SD
was<2.5% of the total particle concentration for serum and<5%
for PF. In both cases, the total particle count increased with the
number of recordings.
Small Changes in Focus Do Not Alter
Particle Count
When looking at serum samples (Figure 8A), if the focus is
increased a small amount away from optimum, i.e., 10 A.U. in our
study, there is a 10% decrease in particle count. If it is decreased
by the same value, there is a 22% decrease. However, if one moves
more substantially away from focus (±30 A.U.), one sees a 63%
drop in particle count on increasing the focus and a 70% decrease
when decreasing it. The same is seen with PF (Figure 8B) where,
if one substantially deviates from the optimum focus, there is
a 22% drop in particle count when increasing the focus and a
25% drop on decreasing it. Examples of screenshots from under-,
over-, and focussed videos (pericardial fluid) are shown in the
Supplementary Figure 1.
Small Variations in Maximum Jump
Distance Do Not Affect Measurements
If the Maximum Jump setting is manually altered to a setting
close to that which the software would automatically select (i.e.,
14) there is no difference in particle count. However, if the
setting is moved further away from this optimal setting in either
direction (i.e., 10 or 20), then variations in particle concentration
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FIGURE 3 | Freezing and thawing affects the recorded particle concentration. Serum particle concentration in the 30–120 nm (A) and 121–210 nm (C) range.
Percentage particles in the 30–120 nm (B) and 121–210 nm range (D) in serum. Total particle concentration in serum (E). Pericardial fluid (PF) particle concentration
in the 30–120 nm (F) and 121–210 nm (G) and total particle concentration (H). T0 = first defrosting of freshly frozen sample, T1 = second defrosting, T2 = third
defrosting, T3 = fourth defrosting. *p < 0.05, **p < 0.01.
are observed. This was seen in both serum (Figure 9A) and
PF (Figure 9B).
DISCUSSION
Our study has investigated the way in which several different
settings or preparation methods immediately prior to sample
analysis have an effect on the particle concentration shown
by NTA using a NanoSight NS300 apparatus, seeking to
compare the effect of the settings or preparations tested on the
same sample.
We have shown that it is possible to use commercially available
sEV standards that, when aliquoted and stored in the same way,
produce repeatable results when run on the NanoSight. If these
are run over the duration of an experiment (days/weeks/months),
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FIGURE 4 | The effect of different diluents on particle count. (A) Serum,
(B) pericardial fluid. Data shown is the particle concentration for the
30–120 nm size range with mean ± SD.
they can be used as a calibrator. In our hands these sEVs appear
stable over the course of several months when stored at−80◦C.
We have also used these commercials EVs to investigate the
linearity of the measurements made by the NanoSight. It is
important, particularly in the case of neat human samples, to
appreciate that there will be variability between patients. This
has implications for the development of any technique which
analyses neat samples, as it will have to be able to take into
account this large variability. We have shown that there is a limit
to with the NanoSight where the increase in particles per frame
no longer gives a linear increase in the particle concentration.
This is in line with the recommendations of the manufacturer
and is likely due to a similar effect to that which we see with large
particle masking. Here, with these particular samples, we suggest
that this range is between approximately 40 and 110 particles per
frame. In order to ensure that one is operating in this range, it
may be necessary to change the dilution of the sample (e.g., due
to variability between samples derived from different patients).
Furthermore, it is possible that this varies from sample type to
sample type. It is, therefore, perhaps prudent for the reader to
carry out an experiment similar to that which we have carried out
in this study to determine the best dilution for their samples. If on
TABLE 2 | Number of completed tracks for each video of plasma calibrator
linearity experiment.
Fold dilution Video recording
1 2 3
20 73516 77511 75046
40 51540 50308 51963
50 73516 77511 75046
66.67 27977 25202 25327
100 26187 26263 26538
125 21032 19986 19967
142.875 19110 19241 19529
200 12516 10241 9769
250 8345 7930 7757
333.33 9593 9205 8742
400 8104 7725 6793
500 6772 5300 4202
800 6088 4239 3379
1000 6770 1975 1984
2000 1091 1295 *
*The concentration of this sample was so low that only two of the three videos gave
any form of measurement.
the one hand best practice indicates to apply the same protocol to
all samples in a study, in the event of observing an overcrowded
sample when running consecutive samples on the NTA the
suggestion would be to adjust the concentration and repeat the
measurement, to ensure that particle concentration is not under-
estimated for that particular sample. This consideration applies
particularly to studies involving patient-derived samples where
variability between patients could be very high (e.g., between
different conditions).
There have been suggestions that sEVs can be degraded or can
aggregate when subjected to repeated freeze/thaw cycles (Zhou
et al., 2006; Muller et al., 2014; Bosch et al., 2016). Our data
suggests that the number of particles in the exosomal range will
increase with repeated freezing and thawing. Potentially, this is
due to the rupture of larger particles into smaller ones that are
then counted in the sEV size range and/or to particles smaller
than the sEV size range, which aggregate and are then counted
within the larger size range. Therefore, it is important to bear this
in mind when processing samples and the reader is encouraged
to both minimise freeze-thaw cycles and to treat all samples
in the same way.
Once the samples have been defrosted, they need to be
diluted in the same manner, at the same concentration. Good
experimental practice dictates that the same pipette type should
be used for making up the same part of the dilution for all the
samples in a given experiment.
The presence of larger particles has been reported to affect
the quantification of smaller (<150 nm) extracellular vesicles in
neat platelet-free plasma even using different techniques (e.g.,
Tunable Resistive Pulse Sensing) (Mørk et al., 2016) and indeed
this is a concern for NTA. This issue can be mitigated by filtering
samples with a 0.22 µm filter prior to running through the
machine, although we accept that there may be some degradation
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FIGURE 5 | Relationship between number of particles per frame tracked by the software and a range of fold dilutions (A), with a range of fold dilutions (66.67 to 250)
where this relationship is linear (R2 = 0.93) and is largely within the range defined by the manufacturer (10–100 particles per frame) (B). This pattern is repeated when
fold dilution is compared with particle concentration (C), where between a fold dilution of 66.67 and 250 this relationship becomes linear (R2 = 0.93) (D).
of larger particles into smaller ones caused by this process. It is
interesting also to note that the effect of filtering may depend on
sample type. The biofluids we present here – serum and PF – are
two contrasting examples. Serum, in our hands, is a particularly
difficult sample to run on NTA and very much requires filtration
prior to running. Pericardial fluid is less difficult, and one might
avoid filtration in many cases. However, if one wishes to compare
data between patients one needs to treat the same sample type in
the same way across different patients. Therefore, we recommend
filtering all samples as a matter of course.
The NanoSight must be focussed accurately before
commencing any recordings, with some degree of tolerance. For
example, we demonstrated that, with serum, an increase of 10
A.U. has only a 10% effect on particle count. However, if this
is increased to 30 A.U., the particle count decreases by 63%.
It is also interesting to note that the effect that this has varies
depending on sample type.
Video length has an impact on the quality of the results
obtained. We have shown that, up to a point, longer video
acquisition allows for capturing more particles, whilst a shorter
video would be more likely be affected (e.g., by an artefact due
to an aggregate) and any small variation would have a bigger
impact on the final total count. On the other hand, longer video
acquisitions result in decreased particle counts. One can speculate
that this may be due to some settling of the particles in the syringe
over time, and/or their binding to the sides of the syringe. Peak
values were recorded using different video lengths for the two
different sample types used, but if one also looks at the standard
deviations of the recorded values, 90 s videos gave the smallest
SDs in both sample types. However, we suggest to the reader that
it is perhaps prudent to run a test as we have done in this study to
determine the optimum video length.
The number of videos recorded and small, reasonable
variations in the Maximum Jump setting did not seem to have
large effects on the results. One would again advocate consistency
across measurements, and not altering the Maximum Jump from
default settings.
With regards to camera gain settings, these were intentionally
not tested as in our opinion they have been sufficiently
discussed elsewhere (Filipe et al., 2010; Gardiner et al., 2013;
Maas et al., 2015).
With regards to data presentation, we have shown particle
concentrations as both absolute numbers of particles, as well
as percentage particles relative to the total concentration. The
total concentration is the total number of particles measured by
the NanoSight in a given measurement. From the perspective
of using this technology on patient-derived samples, this is
useful if, for example, a given acute situation results in an
increase in the number of sEVs released. The presentation of
the results as a percentage of the total particles, on the other
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FIGURE 6 | Filtration eliminates the masking effect of larger particles on
smaller ones. (A) Concentration of latex beads in either monodisperse or
polydisperse preparations. Concentration of particles in the 30–120 nm range
in (B) serum or (C) pericardial fluid, in either unfiltered or filtered preparations.
Data are shown as individual recordings and the mean ± SD. *p < 0.05.
FIGURE 7 | Video length has a noticeable impact on total particle
concentration. (A) Serum, (B) pericardial fluid.
TABLE 3 | Changes in particle concentration and standard deviation in pericardial
fluid and serum samples with different numbers of videos recorded.
Pericardial fluid Serum
Video
number
Particle
concentration
SD Particle
concentration
SD
2 2.54E + 10 9.90E + 08 8.48E + 11 2.83E + 09
3 2.59E + 10 1.16E + 09 8.56E + 11 1.40E + 10
4 2.56E + 10 1.19E + 09 8.64E + 11 1.93E + 10
hand, can give a different and, possibly, complementary picture
to that demonstrated by the absolute quantification. Presenting
the results in this way potentially allows a change in the size of
the particles released due to a given stimulus to be observed.
Indeed, in our cardiac surgery study we saw both these effects
(Emanueli et al., 2016).
We have included a sample script for the NTA software
(Supplementary File 1), along with a sample Standard Operating
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FIGURE 8 | Small changes in focus levels do not have an impact on recorded
particle concentration. Serum (A), pericardial fluid (B).
Procedure (Supplementary File 2). It is important to note
that while we have investigated the effect of sample handling
inasmuch as how freeze-thaw cycles affect the results obtained
through NTA, a complete discussion of sample handling is
beyond the scope of this work and has, indeed, been investigated
elsewhere (Witwer et al., 2013). However, it appears that
when analysing samples using NTA, the adage “junk in, junk
out” applies. It is, therefore, of the utmost importance that
the reader appreciates that poor (or at least inconsistent)
sample handling can have a considerable detrimental effect on
NTA results.
There is documented evidence to suggest that lipoproteins
do, partly, fall into the same size range as small EVs
(Dragovic et al., 2011; Sódar et al., 2016; Mørk et al., 2017; Karimi
et al., 2018) and would therefore interfere with the counts
made by the NanoSight. Unfortunately, the tested apparatus does
not have the capability to use fluorescence staining, so we are
unable to use a fluorescent membrane dye to discern sEVs from
lipoproteins. Data gathered as part of our sample characterisation
revealed that whole serum mimics isolated sEVs; we did
not observe a significant difference in particle concentrations
FIGURE 9 | Small, reasonable changes in “Maximum Jump” settings do not
affect concentration measurements. (A) Serum, (B) pericardial fluid.
between whole serum and isolated sEVs. Moreover, we detected
low level of lipoproteins’ proteins (ApoA1 and ApoB) in serum-
extracted sEVs. This is relevant to report because lipoproteins are
potential contaminants of isolated sEV preparation (Grigor’eva
et al., 2017). Whilst this study is still potentially confounded
by the presence of lipoproteins, given that we have used neat
biofluids, its goal of assessing different machine settings on
human-derived samples is fulfilled and the observations on
machine settings remain valid.
In conclusion, we have investigated the effect of several factors
that could have an effect on the results produced by NTA using
the NanoSight NS300 system, with a focus on clinically-derived
samples. We suggest that the factors that must be controlled when
running experiments on this system are:
1. Freeze thaw cycles of the sample being run,
2. Length of recorded videos,
3. Filtering samples prior to running on the machine to
prevent masking of smaller particles by larger ones,
4. The number of particles per frame in the video recorded
and whether this is in the range of particles per frame where
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the concentration is calculated linearly by the
NanoSight,
5. Using a saline-based diluent (e.g., PBS) to dilute the sample
before running.
The aspects that are less important, but that we advise the
reader to be aware of are:
1. Focus – small variations are acceptable and will not have a
major impact on results, however this can vary depending
on the sample type.
2. “Maximum Jump” settings can set to default values.
3. The number of videos has a minimal impact on particle
counts, however, we would encourage the reader to
record multiple videos (minimum 3), as this will increase
confidence in their results and allow a more representative
volume of the total sample to be analysed.
The use of a calibrator is advised. In this case we have
shown the suitability of commercially available small EVs for this
purpose. If these are prepared, aliquoted and frozen on the same
day they can be used throughout the experiment as a reference
to demonstrate that the machine is producing repeatable results.
This allows the reader to be confident that their data from 1 day
to the next can be compared.
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